Navigation Links
Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
Date:10/31/2008

MONTVALE, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that the NASDAQ Listing Qualifications Panel has granted the Company's request for an extension until December 3, 2008 to comply with the NASDAQ Capital Market minimum market capitalization requirement of $35 million or the alternative requirement of $2.5 million in stockholders' equity in order to remain listed. There can be no assurance that the Company will achieve compliance by the specified deadline.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and, schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties asso
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
2. Scientists synthesize memory in yeast cells
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
5. Scientists synthesize memory in yeast cells
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
8. ASU researchers improve memory devices using nanotech
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
11. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Inc. (Amex:,ADL), headquartered in Tustin, California, with ... its wholly owned subsidiary Jade,Pharmaceutical Inc., is ... development, manufacture and marketing of proprietary pharmaceutical,and ... detailed report on the,Company, its prospects in ...
... Orifice Surgery, AUSTIN, Texas, Oct. 8 ... devices for minimally invasive,surgical procedures conducted through natural ... Series A financing from PTV Sciences, H.I.G.,Ventures, and ... to complete product development and conduct human clinical ...
... Preliminary results from a,clinical study comparing INVEGA(TM) (paliperidone) ... in patients with,recent, acute exacerbation of schizophrenia will ... the 20th Annual U.S. Psychiatric and Mental Health,Congress, ... FL. The poster, entitled "A Comparative Analysis ...
Cached Biology Technology:ValueRich Report on AMDL/China Available on Web Site 2Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing. 2Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing. 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 2Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 4
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... system, every protein made in the cell has a specific ... proteins to their appropriate target. Researchers at Boston University ... images of these channels as they open to allow proteins ... made. These findings are published as a Letter in ...
... apps, cameras, and mobile internet to navigate strange cities in ... in line, and upload their videos directly to social media ... high-tech savvy can save a well-loved device from dying when ... same basic ailment that plagues solar power plants and wind ...
... A drug currently on the market to treat leukemia reversed ... findings by medical researchers with the University of Alberta. ... team,s discovery in the peer-reviewed journal, PLOS ONE . ... can also play an important role in the development of ...
Cached Biology News:Researchers capture images of open channel that moves proteins across cell membranes 2Futuristic copper foam batteries get more bang for the buck 2Futuristic copper foam batteries get more bang for the buck 3UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3
... 10X BlueJuice Gel Loading ... easy loading and tracking ... agarose or native polyacrylamide ... features higher density sucrose ...
Ready-to-use solution....
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: